Genomenon, Inc

🥶 Did you know that the frosty chill of winter is actually detected by a specific gene? Meet TRPM8, also known as the "cold and menthol receptor." This gene encodes a protein found in sensory neurons, acting as a molecular thermometer that senses cold temperatures and menthol-like cooling sensations. When temperatures drop below 25°C (77°F), the TRPM8 receptor is activated, sending signals to our brain that make us feel the cold. This same receptor is also triggered by cooling agents like menthol, which is why menthol feels "cold" on our skin or tongue, even at room temperature. TRPM8 has been linked to pain perception, making it a potential target for pain relief therapies, especially for conditions involving neuropathic pain. 🔎 Learn more about this gene on Mastermind, our Genomic Intelligence Platform: https://lnkd.in/gknxc4zV #GeneFactFriday #TRPM8 #WinterVibes #GenomicsInEverydayLife #Genomenon #Genefacts #MastermindGIP #Genetics #Genomics

This month, we are shining a spotlight on Rett syndrome and providing free access to variant insights for its key causative gene, MECP2. Rett syndrome is a rare neurological disorder that primarily affects young girls, leading to severe cognitive, motor, and communication impairments.  Variants in the MECP2 gene disrupt critical processes in brain development, impacting the ability to walk, speak, and use purposeful hand movements. Early diagnosis and access to precise genetic insights are essential for advancing personalized care and improving patient outcomes. As part of our broader December initiative, we are also offering free variant insights for genes linked to other rare diseases, including Marfan syndrome (FBN1), Ehlers-Danlos syndrome (COL3A1), Fanconi anemia (FANCM), Bloom syndrome (BLM), Infantile Neuroaxonal Dystrophy (PLA2G6), Loeys-Dietz syndrome (SMAD3), Maple Syrup Urine Disease (DBT), Hereditary Hemorrhagic Telangiectasia (ACVRL1), and Bardet-Biedl syndrome (C8ORF37). 🔎 The variant content will be available to all Mastermind users, and anyone can create a free Mastermind account here: https://lnkd.in/g7c_Fzs Learn more about ways to raise awareness from the Rett Syndrome Research Trust 🫶 #RareDiseaseAwareness #RettSyndrome #GenomicResearch #PrecisionMedicine #Genomenon #Mastermind #RareDiseases

In the third installment of our Mastermind Filters series, we’re excited to introduce the Clinical Significance Filters! 🧬 These filters are essential for researchers and clinicians looking to uncover the most relevant genetic insights tied to patient outcomes. With 56 filters divided into four key subcategories—Diagnosis, Prognosis, Therapy, and Clinical Trials—this group allows you to focus on the clinical relevance of genetic variants with precision. - Diagnosis filters focus on identifying disease-associated variants, supporting precise and efficient diagnostic workflows. - Prognosis filters provide data on disease progression, giving you a clearer picture of potential outcomes. - Therapy filters streamline the discovery of treatment-related insights, including drug resistance, inhibitors, compounds, dosage data, receptor interactions, and pharmaceutical associations. - Clinical Trials filters bridge the gap between variant data and ongoing trials, ensuring you never miss an opportunity to explore cutting-edge research. By combining these filters, researchers can refine their searches like never before, saving time while uncovering critical information to support diagnosis, treatment decisions, and research breakthroughs. Whether you’re interpreting variants for clinical care or exploring new therapeutic approaches, Mastermind’s Clinical Significance Filters empower you to find answers faster and more efficiently. Take your genomic research to the next level with Mastermind Professional and discover the impact of precision filtering: https://lnkd.in/gBjTcdHb #GenomicResearch #ClinicalSignificance #GeneticFilters #MastermindGIP #PrecisionMedicine #Genomenon #GenomicInsights

In our latest blog, Genomenon CEO Mike Klein, takes a look back at 2024, highlighting significant milestones our team has achieved over the past year, and our focus to save and improve lives by making genomic evidence actionable - read more: https://lnkd.in/gJ55i87S

🔬 𝐔𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐆𝐞𝐧𝐨𝐦𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐰𝐢𝐭𝐡 𝐀𝐈 🔬 As genomic data expands, so does the challenge of organizing and making it accessible. Genomenon, Inc is addressing this gap with the Genomenon Genomic Graph (G3), an AI-powered knowledgebase that consolidates nearly all published scientific and medical studies, enabling easier access to critical data on genes, variants, treatments, and outcomes. This innovation, the first of its kind, combines patient and biological data, and is set to revolutionize clinical diagnostics, drug development, and real-world evidence applications. By utilizing Genomenon’s curated datasets, G3 reveals novel insights hidden deep within the scientific literature, making previously inaccessible information actionable. 💡 Explore how G3 is changing the game for genomic intelligence, empowering researchers, clinicians, and drug developers alike. For more details, read the full article here: https://lnkd.in/dngSAvCf #Genomics #AI #GenomicData #ClinicalResearch #PrecisionMedicine #Database #Databank #DrugDevelopment #ArtificialIntelligence #Bioinformatics #Medical Mike Klein | Genetic Engineering & Biotechnology News

❣️ Have you ever thought about what makes your heart beat with such precision? The MYH7 gene plays a vital role in controlling the way your heart beats. It encodes a key protein called beta-myosin heavy chain, which is a crucial component of cardiac muscle. This protein allows the heart to contract and pump blood efficiently, keeping your circulatory system running smoothly. Variants in MYH7 are linked to inherited heart conditions like hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). These conditions can affect the heart’s structure and function, sometimes leading to symptoms like shortness of breath or arrhythmias. Thanks to genetic testing, clinicians can now identify MYH7 variants in patients, which helps with early diagnosis, family screening, and more personalized treatment options. It’s a powerful example of how genetic insights are transforming heart health. Visit Mastermind, our genomic intelligence platform to learn more about this gene:  https://lnkd.in/gMXiv29X #GeneFactFriday #MYH7 #Cardiomyopathy #GenomicInsights #GeneticTesting #HeartHealth #PrecisionMedicine #Genomenon #MastermindGIP

We'd like to extend a very warm welcome to our new CFO Brian Groark! 🎉 Brian is an actively licensed CPA and MBA with experience leading finance teams at PE backed technology companies. He has a proven track record of success in financial reporting, fundraising, digital transformations and M&A. Welcome to the Genomenon team, Brian!

This December, we’re supporting rare disease research with free access to variant insights on 10 key causative genes, including DBT, a critical gene linked to Maple Syrup Urine Disease (MSUD). MSUD is a rare genetic disorder caused by variants in DBT, leading to the toxic buildup of amino acids in the body. Early detection is essential to prevent serious complications, making genetic insights vital for research and care. Our December offer also includes complimentary access to variant data for the following genes: MAD2L2, PLA2G6, SMAD3, MECP2, C8ORF37, COL3A1, ACVRL1, FBN1, and BLM. These genes are associated with various conditions that affect patients worldwide, including Marfan syndrome, Fanconi anemia, infantile neuroaxonal dystrophy, Rett syndrome, Ehlers-Danlos syndrome, Bloom syndrome, maple syrup urine disease, Loeys-Dietz syndrome, Bardet-Biedl syndrome, and hereditary hemorrhagic telangiectasia. The variant content will be available to all Mastermind users, and anyone can create a free Mastermind account here: https://lnkd.in/g7c_Fzs #RareDiseaseAwareness #MSUD #GenomicResearch #PrecisionMedicine #Genomenon #MastermindGIP #RareDiseases #DBT

This year, Genomenon's Cancer Knowledgebase (CKB)’s clinical trial coverage has expanded to 39 countries, including 25 newly added European countries. This significant update provides clinicians and researchers with greater access to geographically accessible and genomically relevant clinical trials. 🔗 Read our latest blog to gain an in-depth understanding of how this expansion is transforming access to clinical trials worldwide. Our blog provides a closer look at how CKB is supporting precision oncology and making global clinical trials more accessible than ever before: https://lnkd.in/gvj9bfqQ #ClinicalTrials #PrecisionOncology #CKBExpansion #GlobalHealthImpact #Genomenon #GenomicResearch #CKB

As the amount of genomic data grows, so too does the challenge of organizing it into a usable database. However, the lack of a searchable database of genomic information from the literature has posed a challenge to the research community. Now, Genomenon’s AI-based approach—the Genomenon Genomic Graph (G3) knowledgebase—will combine patient and biological data from nearly all published scientific and medical studies, including demographics, clinical characteristics, phenotypes, treatments, outcomes, and disease-associated genes and variants. Read the latest via Genetic Engineering & Biotechnology News